Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond ...

US drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

Merck agreed to buy respiratory drugmaker Verona for about $10 billion as part of its ongoing search for ways to fill the ...

Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent ...

US stocks trimmed gains on Wednesday after President Trump unveiled more tariff letters directed at US trading partners, ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda. Prosecutors Question Doctors About UnitedHealth's Medicare Billing Practices ...

The U.S. drug giant said that Verona’s Ohtuvayre, which treats chronic obstructive pulmonary disease, will strengthen its lineup of cardiovascular treatments.

Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.